Immune checkpoint signaling and cancer immunotherapy (Q95936576)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32467592%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

title

Immune checkpoint signaling and cancer immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32467592%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32467592%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Xing He

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32467592%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

publication date

28 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32467592%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32467592%20AND%20SRC:MED&resulttype=core&format=json

The Immune Landscape of Cancer.

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Understanding the tumor immune microenvironment (TIME) for effective therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Cancer immunotherapy using checkpoint blockade.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Costimulatory receptors in jawed vertebrates: conserved CD28, odd CTLA4 and multiple BTLAs.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Resistance to checkpoint blockade therapy through inactivation of antigen presentation.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Coordinated protein sorting, targeting and distribution in polarized cells

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Glycosylation-directed quality control of protein folding

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Receptor downregulation and multivesicular-body sorting

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Pathways and mechanisms of endocytic recycling

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

p58(IPK)-mediated attenuation of the proapoptotic PERK-CHOP pathway allows malignant progression upon low glucose.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

TOX for tired T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Deubiquitination and Stabilization of PD-L1 by CSN5.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

T cell receptor-interacting molecule acts as a chaperone to modulate surface expression of the CTLA-4 coreceptor.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Rab8 binding to immune cell-specific adaptor LAX facilitates formation of trans-Golgi network-proximal CTLA-4 vesicles for surface expression.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Exocytosis of CTLA-4 is dependent on phospholipase D and ADP ribosylation factor-1 and stimulated during activation of regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

PD-1 and its ligands in tolerance and immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

PD-L1 Binds to B7-1 Only on the Same Cell Surface

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Molecular mechanism of SHP2 activation by PD-1 stimulation

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

CTLA-4 control over Foxp3+ regulatory T cell function

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Resting lymphocyte kinase (Rlk/Txk) phosphorylates the YVKM motif and regulates PI 3-kinase binding to T-cell antigen CTLA-4

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Protein kinase C-η controls CTLA-4-mediated regulatory T cell function

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteins

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

LAG-3 inhibits the activation of CD4 T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

LAG3 (CD223) as a cancer immunotherapy target

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

LAG3+ Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1+ Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Metalloproteases regulate T-cell proliferation and effector function via LAG-3

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Cutting edge: TIGIT has T cell-intrinsic inhibitory functions

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Vstm3 is a member of the CD28 family and an important modulator of T-cell function

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Unconventional ligand activation of herpesvirus entry mediator signals cell survival

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2.

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

PD-1 regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41422-020-0343-4

7 January 2021

10.1038/S41422-020-0343-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32467592%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32467592%20AND%20SRC:MED&resulttype=core&format=json